Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received a consensus rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $87.6429.

A number of brokerages have commented on HSIC. Morgan Stanley reissued an “underweight” rating and issued a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research note on Wednesday, May 6th. BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Thursday, June 11th. BMO Capital Markets began coverage on Henry Schein in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target on the stock. Finally, UBS Group reaffirmed a “neutral” rating and set a $85.00 price target (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th.

Insider Activity at Henry Schein

In other Henry Schein news, Director William K. Daniel bought 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the second quarter worth approximately $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein during the 2nd quarter worth approximately $27,000. Flagship Harbor Advisors LLC acquired a new position in shares of Henry Schein in the 4th quarter valued at $30,000. Federated Hermes Inc. acquired a new position in shares of Henry Schein in the 4th quarter valued at $32,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Henry Schein in the 4th quarter valued at $37,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Down 0.4%

HSIC stock opened at $85.86 on Wednesday. The company’s 50 day moving average price is $80.18 and its 200 day moving average price is $77.87. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $89.34. The firm has a market capitalization of $9.78 billion, a price-to-earnings ratio of 25.94, a PEG ratio of 1.66 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter last year, the company earned $1.15 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities research analysts anticipate that Henry Schein will post 5.32 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.